Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 40INDUSTRY 4NETWORK 3OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Fallopian Tube Neoplasms 1

Interventions

Cisplatin 49Capecitabine 42Radiotherapy 33Oxaliplatin 33Gemcitabine 33apatinib 32Cyclophosphamide 32Drug Therapy 31Paclitaxel 30Carboplatin 29tislelizumab 27Irinotecan 27Fluorouracil 26Docetaxel 26Bevacizumab 23Surgical Procedures, Operative 20Nivolumab 19pembrolizumab 18fludarabine 18Metformin 16Exercise 16Radiation 15camrelizumab 14S 1 (combination) 14Control Groups 14Blood Specimen Collection 14Pemetrexed 13Standard of Care 12anlotinib 11Neoadjuvant Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Maintenance × Clear all
NCT03983226 2022-03-18

Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

Shanghai Gynecologic Oncology Group

Phase 2 Recruiting
167 enrolled
Gynecologic

Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡